Trial reportTrials2012
Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.
Trial report in Trials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Effects of dengue virus type-2 serotype (DENV-2) on the expression profile of matrix metalloproteinases in THP-1, monocyte cells and their roles in endothelial dysfunctions: protective effect of atorvastatin.Frontiers in cellular and infection microbiology · 2025Article
- The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection.Virology journal · 2024Review
- Studies on the antiviral activity of chebulinic acid against dengue and chikungunya viruses and in silico investigation of its mechanism of inhibition.Scientific reports · 2022Article
- Review
- Dengue: A Minireview.Viruses · 2020Review
- A cocrystal structure of dengue capsid protein in complex of inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Review
- Cardol triene inhibits dengue infectivity by targeting kl loops and preventing envelope fusion.Scientific reports · 2018Article
- Dengue illness index-A tool to characterize the subjective dengue illness experience.PLoS neglected tropical diseases · 2018Article
- Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions.Antiviral research · 2018Article
- Small Molecules and Antibodies for Zika Therapy.The Journal of infectious diseases · 2017Review
- Dengue fever. Clinical features of 567 consecutive patients admitted to a tertiary care center in Saudi Arabia.Saudi medical journal · 2017Article
- Antiviral activity of an N-allyl acridone against dengue virus.Journal of biomedical science · 2015Article
- Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors.Antimicrobial agents and chemotherapy · 2015Article
- Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome.PLoS neglected tropical diseases · 2015Article
- Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.PLoS neglected tropical diseases · 2014Review
- Dengue human infection models supporting drug development.The Journal of infectious diseases · 2014Article
- Cardiovascular manifestations of the emerging dengue pandemic.Nature reviews. Cardiology · 2014Review
- Are there any benefits from statin treatment for the septic patient?Current atherosclerosis reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundDengue is the most important vector-borne viral infection of man, with approximately 2 billion people living in areas at risk. Infection results in a range of manifestations from asymptomatic infection through to life-threatening shock and haemorrhage. One of the hallmarks of severe dengue is vascular endothelial disruption. There is currently no specific therapy and clinical management is limited to supportive care. Statins are a class of drug initially developed for lipid lowering. There has been considerable recent interest in their effects beyond lipid lowering. These include anti-inflammatory effects at the endothelium. In addition, it is possible that lovastatin may have an anti-viral effect against dengue. Observational data suggest that the use of statins may improve outcomes for such conditions as sepsis and pneumonia. This paper describes the protocol for a randomised controlled trial investigating a short course of lovastatin therapy in adult patients with dengue. METHODS/
designA randomised, double-blind, placebo-controlled trial will investigate the effects of lovastatin therapy in the treatment of dengue. The trial will be conducted in two phases with an escalation of dose between phases if an interim safety review is satisfactory. This is an exploratory study focusing on safety and there are no data on which to base a sample size calculation. A target sample size of 300 patients in the second phase, enrolled over two dengue seasons, was chosen based on clinical judgement and feasibility considerations. In a previous randomised trial in dengue, about 10% and 30% of patients experienced at least one serious adverse event or adverse event, respectively. With 300 patients, we will have 80% power to detect an increase of 12% (from 10% to 22%) or 16% (from 30% to 46%) in the frequency of adverse events. Furthermore, this sample size ensures some power to explore the efficacy of statins. DISCUSSION: The development of a dengue therapeutic that can attenuate disease would be an enormous advance in global health. The favourable effects of statins on the endothelium, their good safety profile and their low cost make lovastatin an attractive therapeutic candidate.
trial registrationInternational Standard Randomised Controlled Trial Number ISRCTN03147572.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.